

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: Michel G. Bergeron, et al.

Serial No.: 09/297,539

Filed: May 3, 1999

For: SPECIES-SPECIFIC, GENUS-SPECIFIC AND UNIVERSAL DNA
PROBES AND AMPLIFICATION PRIMERS TO RAPIDLY DETECT
AND IDENTIFY COMMON BACTERIAL AND FUNGAL PATHOGENS
AND ASSOCIATED ANTIBIOTIC RESISTANCE GENES FROM
CLINICAL SPECIMENS FOR DIAGNOSIS IN MICROBIOLOGY
LABORATORIES

Art Unit: 1655

Examiner: Frank Lu

Attorney
Docket No.: 480844.90010

Based On
International
Application: PCT/CA97/00829

PRELIMINARY AMENDMENT ACCOMPANYING CONTINUATION APPLICATION

BOX PATENT APPLICATION
Commissioner for Patents
Washington, D.C. 20231

Dear Sir:

Prior to examination, please enter the following amendments:

IN THE SPECIFICATION:

At page 1, before "BACKGROUND OF THE INVENTION" please insert:

- - This is a continuation of a continued prosecution application filed March 30, 2001 for Application No. 09/297,539 filed May 3, 1999, which is a 371 of PCT/CA97/00829 filed November 4, 1997, which claims priority from U.S. Patent Application No. 08/743,637, filed November 4, 1996. - -

IN THE CLAIMS:

Please cancel claims 1-45.

Please add the following new claims:

46. A method using probes and/or amplification primers which are specific, ubiquitous and sensitive for determining the presence and/or amount of nucleic acids:

- from a bacterial antibiotic resistance gene selected from the group consisting of *bla_{tem}*, *bla_{shv}*, *bla_{rob}*, *bla_{oxa}*, *bla_Z*, *aadB*, *aacC1*, *aacC2*, *aacC3*, *aac6'-IIa*, *aacA4*, *aad(6')*, *vanA*, *vanB*, *vanC*, *msrA*, *satA*, *aac(6')-aph(2'')*, *vat*, *vga*, *ermA*, *ermB*, *ermC*, *mecA*, *int* and *sul*, and

- from specific bacterial and fungal species selected from the group consisting of *Enterococcus faecium*, *Listeria monocytogenes*, *Neisseria meningitidis*, *Streptococcus agalactiae*, *Candida albicans*, *Enterococcus* genus, *Neisseria* genus, *Staphylococcus* genus, *Streptococcus* genus and *Candida* genus,

in any sample suspected of containing said bacterial and/or fungal nucleic acids,

wherein each of said nucleic acid or variant or part thereof comprises a selected target region hybridizable with said probes or primers;

said method comprising the following steps: contacting said sample with said probes or primers under uniform conditions of hybridization or amplification, and detecting the presence and/or amount of hybridized probes or amplified products as an indication of the presence and/or amount of said specific bacterial and/or fungal species or genus simultaneously with said bacterial antibiotic resistance genes.

47. A method according to claim 46, which further makes use of probes and/or primers which are specific, ubiquitous and sensitive for simultaneously determining the presence and/or amount of nucleic acids from any bacterium or fungus.

0999643-112001
FOO2T" 2496660

48. The method of claim 46, which is performed directly from a test sample.

49. The method of claim 46, which is performed directly from a test sample consisting of a bacterial and/or fungal culture or suspension.

50. The method of claim 46, wherein said nucleic acids are amplified by a method selected from the group consisting of:

- a) polymerase chain reaction (PCR),
- b) ligase chain reaction (LCR),
- c) nucleic acid sequence-based amplification (NASBA),
- d) self-sustained sequence replication (3SR),
- e) strand displacement amplification (SDA),
- f) branched DNA signal amplification (bDNA),
- g) transcription-mediated amplification (TMA),
- h) cycling probe technology (CPT),
- i) nested PCR, and
- j) multiplex PCR.

51. The method of claim 46, wherein said nucleic acids are amplified by PCR.

52. The method of claim 46, wherein the PCR protocol achieves within one hour under uniform amplification conditions the determination of the presence of said nucleic acids by performing for each amplification cycle an annealing step of thirty seconds at 45-55°C and a denaturation step of only one second at 95°C without any time specifically allowed to an elongation step.

53. A method for the detection, identification and/or quantification of a microorganism selected from the group consisting of *Enterococcus faecium*, *Listeria monocytogenes*, *Neisseria meningitidis*, *Staphylococcus saprophyticus*, *Streptococcus agalactiae*, *Candida albicans*, *Enterococcus* species, *Neisseria*

species, *Staphylococcus* species, *Streptococcus* species and *Candida* species, directly from a test sample or from bacterial and/or fungal cultures, which comprises the following steps:

a) depositing and fixing on an inert support or leaving in solution the said microorganism DNA of the sample or of a substantially homogeneous population of said microorganism isolated from this sample, or

inoculating said sample or said substantially homogeneous population of microorganism isolated from this sample on an inert support, and lysing *in situ* said inoculated sample or said isolated microorganism to release the said microorganism DNA,

said microorganism DNA being made in a substantially single-stranded form;

b) contacting said single-stranded DNA with a probe, said probe comprising at least one single-stranded nucleic acid which nucleotide sequence is selected from the group consisting of SEQ ID NOs: 26, 27, 28, 29, 30, 120, 131 to 134, 31, 140 to 143, 32 to 36, 120 to 124, a sequence complementary thereof, a part thereof having at least 12 nucleotides in length, and a variant thereof, which specifically and ubiquitously anneals with strains or representatives of *Enterococcus faecium*, *Listeria monocytogenes*, *Neisseria meningitidis*, *Staphylococcus saprophyticus*, *Streptococcus agalactiae*, *Candida albicans*, *Enterococcus* species, *Neisseria* species, *Staphylococcus* species, *Streptococcus* species and *Candida* species, respectively, under conditions such that the nucleic acid of said probe can selectively hybridize with said microorganism DNA, whereby a hybridization complex is formed; and

c) detecting the presence of said hybridization complex on said inert support or in said solution as an indication of the presence and/or amount of said microorganism, in said test sample.

54. A method for detecting the presence and/or amount of a microorganism selected from the group consisting of *Enterococcus faecium*, *Listeria*

monocytogenes, *Neisseria meningitidis*, *Staphylococcus saprophyticus*, *Streptococcus agalactiae*, *Candida albicans*, *Enterococcus* species, *Neisseria* species, *Staphylococcus* species, *Streptococcus* species and *Candida* species, in a test sample which comprises the following steps:

a) treating said sample with an aqueous solution containing at least one pair of oligonucleotide primers having at least 12 nucleotides in length, one of said primers being capable of hybridizing selectively with one of the two complementary strands of said microorganism DNA that contains a target sequence, and the other of said primers being capable of hybridizing with the other of said strands so as to form an extension product which contains the target sequence as a template, said at least one pair of primers being chosen from a nucleotide sequence within the group consisting of SEQ ID NOs: 26, 27, 28, 29, 30, 120, 131 to 134, 31, 140 to 143, 32 to 36, 120 to 124, respectively with regard to said microorganism, a sequence complementary thereof, and a variant thereof;

b) synthesizing an extension product of each of said primers, said extension product containing the target sequence, and amplifying said target sequence, if any, to a detectable level; and

c) detecting the presence and/or amount of said amplified target sequence as an indication of the presence and/or amount of said microorganisms, in said test sample.

55. The method of claim 54 wherein said pair of primers is defined in SEQ ID NOs: 1 and 2, 3 and 4, 5 and 6, 7 and 8, 9 and 10, 11 and 12, 13 and 14, 15 and 16, 17 to 20, 21 and 22, respectively, for each of *Enterococcus faecium*, *Listeria monocytogenes*, *Neisseria meningitidis*, *Staphylococcus saprophyticus*, *Streptococcus agalactiae*, *Candida albicans*, *Enterococcus* species, *Neisseria* species, *Staphylococcus* species and *Streptococcus* species.

56. A method for detecting the presence and/or amount of any bacterium directly from a test sample or a bacterial culture, which comprises the following steps:

a) depositing and fixing on an inert support or leaving in solution the bacterial DNA of the sample or of a substantially homogeneous population of bacteria isolated from this sample, or

inoculating said sample or said substantially homogeneous population of bacteria isolated from this sample on an inert support, and lysing *in situ* said inoculated sample or isolated bacteria to release the bacterial DNA,

said bacterial DNA being made in a substantially single-stranded form;

b) contacting said single-stranded DNA with a probe, said probe comprising at least one single-stranded nucleic acid which nucleotide sequence is selected from the group consisting of SEQ ID NOs: 118, 119, 125 to 171, a sequence complementary thereof, a part thereof having at least 12 nucleotides in length, and a variant thereof, which specifically and ubiquitously anneals with strains or representatives of any bacterial species, under conditions such that the nucleic acid of said probe can selectively hybridize with said bacterial DNA, whereby a hybridization complex is formed; and

c) detecting the presence of said hybridization complex on said inert support or in said solution as an indication of the presence and/or amount of any bacterium in said test sample.

57. A method for detecting the presence and/or amount of any bacterium in a test sample which comprises the following steps:

a) treating said sample with an aqueous solution containing at least one pair of oligonucleotide primers having at least 12 nucleotides in length, one of said primers being capable of hybridizing selectively with one of the two complementary strands of any bacterial DNA that contains a target sequence, and the other of said primers being capable of hybridizing with the other of said strands so as to form an extension product which contains the target sequence

as a template, said at least one pair of primers being chosen from a nucleotide sequence within the group consisting of SEQ ID NO: 118, 119, 125 to 171, a sequence complementary thereof, and a variant thereof;

b) synthesizing an extension product of each of said primers, said extension product containing the target sequence, and amplifying said target sequence, if any, to a detectable level; and

c) detecting the presence and/or amount of said amplified target sequence as an indication of the presence and/or amount of any bacterium in said test sample.

58. The method of claim 57, wherein said pair of primers is defined in SEQ ID NOs: 23 and 24.

59. A method for obtaining *tuf* sequences from any bacterium directly from a test sample or a bacterial culture, which comprises the following steps:

a) treating said sample with an aqueous solution containing a pair of primers having a sequence selected within the nucleotide sequences defined in SEQ ID NOs: 107 and 108, a part thereof having at least 12 nucleotides in length, a sequence complementary thereof, and a variant thereof, one of said primers being capable of hybridizing selectively with one of the two complementary strands of said bacterial *tuf* gene that contains a target sequence, and the other of said primers being capable of hybridizing with the other of said strands so as to form an extension product which contains the target sequence as a template;

b) synthesizing an extension product of each of said primers, said extension product containing the target sequence, and amplifying said target sequence, if any, to a detectable level; and

c) detecting the presence and/or amount of said amplified target sequence; and

d) determining the nucleotide sequence of the said amplified target sequence by using any DNA sequencing method.

09969643 112001
T00217 E4963660

60. A method for detecting the presence and/or amount of any fungus directly from a test sample or a fungal culture, which comprises the following steps:

a) depositing and fixing on an inert support or leaving in solution the fungal DNA of the sample or of a substantially homogeneous population of fungi isolated from this sample, or

inoculating said sample or said substantially homogeneous population of fungi isolated from this sample on an inert support, and lysing *in situ* said inoculated sample or isolated fungi to release the fungal DNA,

said fungal DNA being made in a substantially single-stranded form;

b) contacting said single-stranded DNA with a probe, said probe comprising at least one single-stranded nucleotide sequence selected from the group consisting of SEQ ID NOs: 120 to 124, a sequence complementary thereof, a part thereof having at least 12 nucleotides in length, and a variant thereof, which specifically and ubiquitously anneals with strains or representatives of any fungus, under conditions such that the nucleic acid of said probe can selectively hybridize with said fungal DNA, whereby a hybridization complex is formed; and

c) detecting the presence of said hybridization complex on said inert support or in said solution as an indication of the presence and/or amount of any fungus in said test sample.

61. A method for detecting the presence and/or amount of any fungus in a test sample which comprises the following steps:

a) treating said sample with an aqueous solution containing at least one pair of oligonucleotide primers having at least 12 nucleotides in length, one of said primers being capable of hybridizing selectively with one of the two complementary strands of any fungal DNA that contains a target sequence, and the other of said primers being capable of hybridizing with the other of said strands so as to form an extension product which contains the target sequence as a template, said at least one pair of primers being chosen from a nucleotide

sequence within the group consisting of SEQ ID NOs: 120 to 124, a sequence complementary thereof, and a variant thereof;

b) synthesizing an extension product of each of said primers, said extension product containing the target sequence, and amplifying said target sequence, if any, to a detectable level; and

c) detecting the presence and/or amount of said amplified target sequence as an indication of the presence and/or amount of any fungus in said test sample.

62. A method for obtaining *tuf* sequences from any fungus directly from a test sample or a fungal culture, which comprises the following steps:

a) treating said sample with an aqueous solution containing a pair of primers having a sequence selected within the nucleotide sequence defined in SEQ ID NOs: 109 and 172, a part thereof having at least 12 nucleotides in length, a sequence complementary thereof, and a variant thereof, one of said primers being capable of hybridizing selectively with one of the two complementary strands of said fungal *tuf* gene that contains a target sequence, and the other of said primers being capable of hybridizing with the other of said strands so as to form an extension product which contains the target sequence as a template;

b) synthesizing an extension product of each of said primers, said extension product containing the target sequence, and amplifying said target sequence, if any, to a detectable level; and

c) detecting the presence and/or amount of said amplified target sequence; and

d) determining the nucleotide sequence of the said amplified target sequence by using any DNA sequencing method.

63. A method as defined in claim 46, which comprises the evaluation of the presence of a bacterial resistance mediated by a bacterial antibiotic resistance gene selected from the group consisting of *bla_{oxa}*, *blaZ*, *aac6'-IIa*, *ermA*, *ermB*,

ermC, *vanB*, *vanC*, directly from a test sample or a bacterial culture, which comprises the following steps:

a) depositing and fixing on an inert support or leaving in solution the bacterial DNA of the sample or of a substantially homogeneous population of bacteria isolated from this sample, or

inoculating said sample or said substantially homogeneous population of bacteria isolated from this sample on an inert support, and lysing *in situ* said inoculated sample or isolated bacteria to release the bacterial DNA,

said bacterial DNA being made in a substantially single-stranded form;

b) contacting said single-stranded DNA with a probe, said probe comprising at least one single-stranded nucleotide sequence having at least 12 nucleotide in length is selected from the group consisting of SEQ ID NOs: 110, 111, 112, 113, 114 115, 116, 117, a sequence complementary thereof, and a variant thereof, which specifically hybridizes with said bacterial antibiotic resistance gene, respectively; and

c) detecting the presence of a hybridization complex as an indication of a bacterial resistance mediated by said one of said bacterial antibiotic resistance genes.

64. A method as defined in claim 46, which comprises the evaluation of the presence of a bacterial resistance mediated by a bacterial antibiotic resistance gene selected from the group consisting of *bla_{oxa}*, *blaZ*, *aac6'-IIa*, *ermA*, *ermB*, *ermC*, *vanB*, *vanC*, directly from a test sample or a bacterial culture, which comprises the following steps:

a) treating said sample with an aqueous solution containing at least one pair of primers having at least 12 nucleotides in length, one of said primers being capable of hybridizing selectively with one of the two complementary strands of said bacterial antibiotic resistance gene that contains a target sequence, and the other of said primers being capable of hybridizing with the other of said strands so as to form an extension product which contains the target sequence as a

b) synthesizing an extension product of each of said primers, said extension product containing the target sequence, and amplifying said target sequence, if any, to a detectable level; and

c) detecting the presence and/or amount of said amplified target sequence as an indication of a bacterial resistance mediated by one of said bacterial antibiotic resistance genes.

66. A nucleic acid having the nucleotide sequence of any one of SEQ ID NOs: 26 to 36, 110 to 117, a part thereof, a sequence complementary thereof, and variant thereof which, when in single-stranded form, ubiquitously and specifically hybridizes with a target bacterial or fungal DNA as a probe or as a primer.

67. An oligonucleotide having the nucleotide sequence of any one of SEQ ID NOs: 1 to 25, 37 to 71, 73 to 109 and 172 to 174, a part thereof, a sequence complementary thereof, and variant thereof, which ubiquitously and specifically hybridizes with a target bacterial or fungal DNA as a probe or as a primer.

68. A recombinant plasmid comprising a nucleic acid as defined in claim 67.

69. A recombinant host which has been transformed by a recombinant plasmid according to claim 68.

70. A recombinant host according to claim 69 wherein said host is *Escherichia coli*.

71. A diagnostic kit for the detection and/or quantification of the nucleic acids of any combination of the microbial species and/or genera selected from the group consisting of *Enterococcus faecium*, *Listeria monocytogenes*, *Neisseria meningitidis*, *Staphylococcus saprophyticus*, *Streptococcus agalactiae*, *Candida albicans*, *Enterococcus* species, *Neisseria* species, *Staphylococcus* species,

Streptococcus species and *Candida* species, comprising any suitable combination of probes of at least 12 nucleotides in length selected from the group consisting of SEQ ID NOs: 26 to 36, 120 to 124, 131 to 134, 140 to 143, sequences complementary thereof, and variants thereof.

72. A diagnostic kit for the detection and/or quantification of the nucleic acids of any combination of the microbial species and/or genera selected from the group consisting of *Enterococcus faecium*, *Listeria monocytogenes*, *Neisseria meningitidis*, *Staphylococcus saprophyticus*, *Streptococcus agalactiae*, *Candida albicans*, *Enterococcus* species, *Neisseria* species, *Staphylococcus* species, *Streptococcus* species and *Candida* species, comprising any suitable combination of primers of at least 12 nucleotides in length selected from the group consisting of SEQ ID NOs: 26 to 36, 120 to 124, 131 to 134, 140 to 143, sequences complementary thereof, and variants thereof.

73. A diagnostic kit for the detection and/or quantification of the nucleic acids of any combination of the microbial species and/or genera selected from the group consisting of *Enterococcus faecium*, *Listeria monocytogenes*, *Neisseria meningitidis*, *Staphylococcus saprophyticus*, *Streptococcus agalactiae*, *Candida albicans*, *Enterococcus* species, *Neisseria* species, *Staphylococcus* species and *Streptococcus* species, comprising any suitable combination of primers selected from the group consisting of SEQ ID NOs: 1 to 22, parts thereof having at least 12 nucleotides in length, sequences complementary thereof, and variants thereof.

74. A diagnostic kit for the detection and/or quantification of the nucleic acids of any combination of the bacterial resistance genes selected from the group consisting of *bla_{oxa}*, *blaZ*, *aac6'-IIa*, *ermA*, *ermB*, *ermC*, *vanC*, comprising any suitable combination of probes of at least 12 nucleotides in length selected from the group consisting of SEQ ID NOs: 110 to 115 and 117, sequences complementary thereof, and variants thereof.

75. A diagnostic kit for the detection and/or quantification of the nucleic acids of any combination of the bacterial resistance genes selected from the group consisting of *bla_{oxa}*, *blaZ*, *aac6'-IIa*, *ermA*, *ermB*, *ermC*, *vanC*, comprising any suitable combination of primers of at least 12 nucleotides in length selected from the group consisting of SEQ ID NOs: 110 to 115 and 117, sequences complementary thereof, and variants thereof.

76. A diagnostic kit for the detection and/or quantification of the nucleic acids of any bacterium and/or fungus, comprising any combination of probes of at least 12 nucleotides in length selected upon alignment of conserved nucleotides of at least two sequences of the group consisting of SEQ ID NOs: 118 to 171, sequences complementary thereof, and variants thereof.

77. A diagnostic kit for the detection and/or quantification of the nucleic acids of any bacterium and/or fungus, comprising any suitable combination of primers of at least 12 nucleotides in length selected upon alignment of conserved nucleotides of at least two sequences the group consisting of SEQ ID NOs: 118 to 171, sequences complementary thereof, and variants thereof.

78. A diagnostic kit for the detection and/or quantification of the nucleic acids of any bacterium, comprising a pair of primers having a sequence selected within the nucleotide sequence defined in SEQ ID NOs: 23 and 24, parts thereof having at least 12 nucleotides in length, sequences complementary thereof, and variants thereof.

79. A diagnostic kit, as defined in claim 71, further comprising any combination of probes of at least 12 nucleotides in length selected within a nucleotide sequence from the group consisting of SEQ ID NOs: 118 to 171, sequences complementary thereof, and variants thereof, for the simultaneous detection and/or quantification of nucleic acids of any bacterium and/or fungus.

80. A diagnostic kit, as defined in claim 72, further comprising any suitable combination of primers of at least 12 nucleotides in length selected within a nucleotide sequence from the group consisting of SEQ ID NOs: 118 to 171, sequences complementary thereof, and variants thereof, for the simultaneous detection and/or quantification of nucleic acids of any bacterium and/or fungus.

81. A diagnostic kit, as defined in claim 73, further comprising a pair of primers having a sequence selected within the nucleotide sequence defined in SEQ ID NOs: 23 and 24, parts thereof having at least 12 nucleotides in length, sequences complementary thereof, and variants thereof, for the simultaneous detection and/or quantification of nucleic acids of any bacterium.

82. A diagnostic kit, as defined in claim 71, further comprising any combination of probes of at least 12 nucleotides in length selected within a nucleotide sequence from the group consisting of SEQ ID NOs: 110 to 117, sequences complementary thereof, and variants thereof, for the simultaneous detection and/or quantification of nucleic acids of any bacterial antibiotic resistance gene selected from the group consisting of *bla_{oxa}*, *blaZ*, *aac6'-IIa*, *ermA*, *ermB*, *ermC*, *vanB*, *vanC*.

83. A diagnostic kit, as defined in claim 72, further comprising any suitable combination of primers of at least 12 nucleotides in length selected within a nucleotide sequence from the group consisting of SEQ ID NOs: 110 to 117, sequences complementary thereof, and variants thereof, for the simultaneous detection and/or quantification of nucleic acids of any bacterial antibiotic resistance gene selected from the group consisting of *bla_{oxa}*, *blaZ*, *aac6'-IIa*, *ermA*, *ermB*, *ermC*, *vanB*, *vanC*.

84. A diagnostic kit, as defined in claim 73, further comprising any suitable combination of primers of at least 12 nucleotides in length selected within a

	1980	1981	1982	1983	1984	1985	1986	1987	1988	1989	1990	1991	1992	1993	1994	1995	1996	1997	1998	1999	2000	2001	2002	2003	2004	2005	2006	2007	2008	2009	2010	2011	2012	2013	2014	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025	2026	2027	2028	2029	2030	2031	2032	2033	2034	2035	2036	2037	2038	2039	2040	2041	2042	2043	2044	2045	2046	2047	2048	2049	2050	2051	2052	2053	2054	2055	2056	2057	2058	2059	2060	2061	2062	2063	2064	2065	2066	2067	2068	2069	2070	2071	2072	2073	2074	2075	2076	2077	2078	2079	2080	2081	2082	2083	2084	2085	2086	2087	2088	2089	2090	2091	2092	2093	2094	2095	2096	2097	2098	2099	2100	2101	2102	2103	2104	2105	2106	2107	2108	2109	2110	2111	2112	2113	2114	2115	2116	2117	2118	2119	2120	2121	2122	2123	2124	2125	2126	2127	2128	2129	2130	2131	2132	2133	2134	2135	2136	2137	2138	2139	2140	2141	2142	2143	2144	2145	2146	2147	2148	2149	2150	2151	2152	2153	2154	2155	2156	2157	2158	2159	2160	2161	2162	2163	2164	2165	2166	2167	2168	2169	2170	2171	2172	2173	2174	2175	2176	2177	2178	2179	2180	2181	2182	2183	2184	2185	2186	2187	2188	2189	2190	2191	2192	2193	2194	2195	2196	2197	2198	2199	2200	2201	2202	2203	2204	2205	2206	2207	2208	2209	2210	2211	2212	2213	2214	2215	2216	2217	2218	2219	2220	2221	2222	2223	2224	2225	2226	2227	2228	2229	2230	2231	2232	2233	2234	2235	2236	2237	2238	2239	2240	2241	2242	2243	2244	2245	2246	2247	2248	2249	2250	2251	2252	2253	2254	2255	2256	2257	2258	2259	2260	2261	2262	2263	2264	2265	2266	2267	2268	2269	2270	2271	2272	2273	2274	2275	2276	2277	2278	2279	2280	2281	2282	2283	2284	2285	2286	2287	2288	2289	2290	2291	2292	2293	2294	2295	2296	2297	2298	2299	2300	2301	2302	2303	2304	2305	2306	2307	2308	2309	2310	2311	2312	2313	2314	2315	2316	2317	2318	2319	2320	2321	2322	2323	2324	2325	2326	2327	2328	2329	2330	2331	2332	2333	2334	2335	2336	2337	2338	2339	2340	2341	2342	2343	2344	2345	2346	2347	2348	2349	2350	2351	2352	2353	2354	2355	2356	2357	2358	2359	2360	2361	2362	2363	2364	2365	2366	2367	2368	2369	2370	2371	2372	2373	2374	2375	2376	2377	2378	2379	2380	2381	2382	2383	2384	2385	2386	2387	2388	2389	2390	2391	2392	2393	2394	2395	2396	2397	2398	2399	2400	2401	2402	2403	2404	2405	2406	2407	2408	2409	2410	2411	2412	2413	2414	2415	2416	2417	2418	2419	2420	2421	2422	2423	2424	2425	2426	2427	2428	2429	2430	2431	2432	2
--	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	---

86. A diagnostic kit, as defined in claim 75, further comprising any suitable combination of primers of at least 12 nucleotides in length selected within a nucleotide sequence from the group consisting of SEQ ID NOs: 116 and 118 to 171, sequences complementary thereof, and variants thereof, for the simultaneous detection and/or quantification of nucleic acids of vancomycin B gene and of any bacterium and/or fungus, respectively.

-16-

the simultaneous detection and/or quantification of nucleic acids of any bacterium.

88. A diagnostic kit, as defined in claim 76, further comprising any combination of probes of at least 12 nucleotides in length selected within a nucleotide sequence from the group consisting of SEQ ID NOs: 118 to 171, sequences complementary thereof, and variants thereof, for the simultaneous detection and/or quantification of nucleic acids of any bacterium and/or fungus.

89. A diagnostic kit, as defined in claim 72, further comprising any suitable combination of primers of at least 12 nucleotides in length selected within a nucleotide sequence from the group consisting of SEQ ID NOs: 118 to 171, sequences complementary thereof, and variants thereof, for the simultaneous detection and/or quantification of nucleic acids of any bacterium and/or fungus.

90. A diagnostic kit, as defined in claim 73, further comprising a pair of primers having a sequence selected within the nucleotide sequence defined in SEQ ID NOs: 23 and 24, parts thereof having at least 12 nucleotides in length, sequences complementary thereof, and variants thereof, for the simultaneous detection and/or quantification of nucleic acids of any bacterium.

Remarks

The new claims have been added to remove the multiple dependencies in claims 1-45 that were submitted in response to the Written Opinion in PCT/CA97/00829 filed November 4, 1997. No new matter has been introduced into the application.

The Commissioner is hereby authorized to charge any fees which may be required, or credit any overpayment, to Deposit Account No. 17-0055.

Respectfully submitted,

Dated: November 20, 2001

By Richard T. Roche

Richard T. Roche
QUARLES & BRADY LLP
411 East Wisconsin Avenue
Milwaukee, WI 53202
Reg. No.: 38,599
(414) 277-5000

0909043-112001
FOOTNOTES 11/2001